Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

Key facts

Sponsor

Thomas E. Ahlering

Principal Investigator

Thomas Ahlering, MD

Professor

Intervention

eflornithine(drug)

Enrollment

76 target

Eligibility

35-70 years · MALE

Timeline

1998 – 2012

Study locations (1)

• Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center, Orange, California, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Familial prostate cancer

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT06470685
  Prophylactic Prostatectomy for Prostate Cancer (PPPC)
  Royal Marsden NHS Foundation Trust
• RECRUITINGNCT06433349
  A Multi-center Investigation of Family Health.
  Odense University Hospital
• RECRUITINGNANCT06171139
  Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
  University of California, San Francisco
• ACTIVE NOT RECRUITINGNANCT04763915
  Improving Care After Inherited Cancer Testing
  Vanderbilt-Ingram Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT04090528
  pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
  University of Wisconsin, Madison
• ACTIVE NOT RECRUITINGPHASE2NCT03725761
  Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
  University of Wisconsin, Madison
• RECRUITINGNCT01221168
  Epidemiologic and Genetic Study on Familial Prostate Cancer
  Centre de Recherche sur les Pathologies Prostatiques

See all trials for Familial prostate cancer →